A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000

Director Emma Reeve of PTC Therapeutics (NASDAQ:PTCT) exercised 10,000 banal options and instantly sold the underlying shares for a full worth of astir $795,000, reducing her nonstop holdings to 6,666 shares according to the SEC Form 4 filing.

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($79.50).

• What was the operation and intent of this transaction?
  This transaction progressive the workout of 10,000 banal options by Emma Reeve, followed by the contiguous merchantability of each underlying shares.

• How important was the simplification successful nonstop ownership?
  The merchantability represented 60.00% of Reeve’s nonstop holdings instantly anterior to the transaction, leaving her with 6,666 shares, oregon astir 0.0083% nonstop ownership arsenic of Nov. 21, 2025. This marks a worldly alteration successful her vulnerability to PTC Therapeutics.

• How does this merchantability comparison to Reeve’s humanities activity?
  Since Sept. 11, 2025, Reeve’s nonstop holdings person declined by astir 92%, chiefly done a bid of enactment exercises and administrative transactions. The 10,000 shares sold successful this filing is successful enactment with her caller signifier of reducing holdings via periodic option-related sales.

• What was the marketplace situation astatine the clip of the sale?
  Shares were priced astatine $79.50 for this transaction, compared to $82.93 arsenic of Nov. 25, 2025. The one-year full instrumentality arsenic of the transaction day was 83.00%, indicating beardown stock terms appreciation successful the play starring up to the sale.

Note: 1-year terms alteration calculated utilizing Nov. 21, 2025, arsenic the notation date.

• PTC Therapeutics generates gross done the commercialization of treatments for uncommon familial disorders, including Translarna and Emflaza for Duchenne muscular dystrophy, arsenic good arsenic Tegsedi, Waylivra, and Evrysdi for different uncommon diseases.

• The institution operates a biopharmaceutical concern exemplary focused connected cause discovery, objective development, and planetary commercialization, leveraging collaborations with large pharmaceutical partners to grow its merchandise portfolio and reach.

• Primary customers see healthcare providers, hospitals, and authorities agencies treating patients with uncommon diseases, peculiarly successful North America, Europe, and Latin America.